Status:
COMPLETED
A 10-Week Study for Efficacy and Safety Study of Gabitril in the Treatment of Adults With Generalized Anxiety Disorder
Lead Sponsor:
Cephalon
Conditions:
Generalized Anxiety Disorder
Eligibility:
All Genders
18-64 years
Phase:
PHASE3
Brief Summary
The purpose of this study is to evaluate the safety and efficacy of an investigational anti-anxiety medication relative to placebo in patients with generalized anxiety disorder (GAD).
Eligibility Criteria
Inclusion
- • Subjects 18 to 64 years of age (inclusive) will be eligible to participate if they satisfy the DSM-IV-TR criteria for GAD, as well as meeting the required screening and baseline visit scores for a series of psychiatric evaluations (i.e., HAM-A, HADS, MADRS and CGI-S).
Exclusion
- Have been previously unresponsive to two or more adequate courses of pharmacological treatment for GAD
- Have been diagnosed with any other psychiatric Axis I disorder (except GAD) as a principal diagnosis within the past six months
- Have been diagnosed with any eating disorder within the past six months
- Have any history of OCD, psychotic disorder, bipolar disorder or antisocial personality disorder
- Have any history of alcohol or substance abuse within 3 months of screening
- Have any history of seizures, including febrile seizures
- Have any history of head trauma associated with loss of consciousness within the past 15 years
Key Trial Info
Start Date :
October 1 2004
Trial Type :
INTERVENTIONAL
End Date :
March 1 2006
Estimated Enrollment :
440 Patients enrolled
Trial Details
Trial ID
NCT00236067
Start Date
October 1 2004
End Date
March 1 2006
Last Update
May 9 2014
Active Locations (21)
Enter a location and click search to find clinical trials sorted by distance.
1
Birmingham Research Group
Birmingham, Alabama, United States, 35216
2
Southwestern Research Institute
Beverly Hills, California, United States, 90210
3
Pharmacology Research Institute
Northridge, California, United States, 91324
4
Pacific Clinical Research
Orange, California, United States, 92868